Guildford, United Kingdom

ANGLE is a specialist diagnostics company. Its proprietary Parsortix technology can capture and harvest very rare cells, including CTCs (circulating tumour cells), from a blood sample. The FDA approval for its clinical use to guide precision cancer care will open up further multiple commercial opportunities.

Investment Perspective

ANGLE’s H121 results confirm progress of its proprietary Parsortix cancer diagnostic platform across multiple fronts. Whilst attention inevitably focusses on the expected upcoming FDA approval for use in metastatic breast cancer, important progress has been achieved with developing the ovarian cancer LDT (Laboratory Developed Test). UK and US clinical laboratories, created ahead of schedule, are anticipated to receive certification by year-end. This will drive nearer term revenues from pharma services, demonstrate the clinical value, and validate the proposition for larger commercial labs. Collectively these efforts will help shape Parsortix’s positioning in the emerging, and dynamic, liquid biopsy market. We value ANGLE at £581m ($755m), 248p/share.

Market information

SymbolPrimary exchanges


FDA approval awaited, LDT data expected H122
Update | 17 Jan 2022
Poised to disrupt existing tumour assay protocols
Update | 01 Oct 2021
First custom CTC assay development contract
Lighthouse | 29 Jul 2021

Recent News

Concordance of Parsortix with tissue biopsy
17 Jan 2022
Update on lab accreditation and ovarian study
13 Jan 2022
Insight into drug resistance in NSCLC
10 Jan 2022
Parsortix in RNA analysis of CTCs as tool in NSCLC
01 Dec 2021